arrow
D

D Popa

‘victor babes’ university of medicine and pharmacy
H指数:6
被引数:127

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Carbapenem-Resistant and Extensively Drug-Resistant Gram-Negative Healthcare-Associated Infections in a Romanian Tertiary Infectious Diseases Hospital: Phenotypic Landscape, Stewardship Gaps and Outcomes (2024–2025)

碳青霉烯耐药和广泛耐药革兰阴性菌医疗相关性感染的罗马尼亚三级传染病医院:表型景观、 stewardship 缺口和结局(2024–2025)

2026-10-120
OA
Cardiovascular Risk in Psoriatic Arthritis in the Treat-to-Target Era: A Focused Expert Narrative Review of Epidemiology, Risk Assessment, Vascular Imaging, and Prevention

银屑病关节炎在目标治疗时代的心血管风险:一项关于流行病学、风险评估、血管成像和预防的聚焦专家叙事综述

2026-09-190
OA
HEART Score Distribution and Association with In-Hospital Management and Outcomes in COVID-19 Survivors Presenting with Acute Chest Pain

HEART评分分布及其与COVID-19幸存者急性胸痛住院管理和预后的关系

2026-09-140
OA
Association Between Vitamin D Status, Metabolic Syndrome, and Menopausal Type: A Comparative Observational Study in Women with Early and Physiological Menopause

维生素D状态、代谢综合征与绝经类型之间的关联:一项针对早期和生理性绝经女性的比较观察研究

2026-08-010
OA
Hyperuricemia Reflects Cardiometabolic Burden Rather than Left Ventricular Systolic Dysfunction Across Heart Failure Phenotypes: Insights from a Real-World Acute Heart Failure Cohort

高尿酸血症反映心脏代谢负担而非左心室收缩功能障碍:来自真实世界急性心力衰竭队列的见解

2026-07-230
OAAI
Pre-Existing Heart Failure, Biomarker Profiles, and Patients’ Vulnerability in Hospitalized COVID-19: A Biomarker-Driven Risk Framework

基础性心力衰竭、生物标志物谱与住院COVID-19患者的脆弱性:一种生物标志物驱动的风险框架

2026-03-040
OAAI
Hungry Bone Syndrome After Parathyroidectomy for Secondary Hyperparathyroidism: Pathogenesis and Contemporary Clinical Considerations

继发性甲状旁腺功能亢进行甲状旁腺切除术后饥饿骨综合征:发病机制与现代临床考量

2025-10-090
OAAI